Mesoblast (ASX:MSB) share price soars 14% on clinical trial results

The Mesoblast share price soared today as the company announced positive clinical trial results. We take a closer look.

| More on:
asx share price rise represented by man holding bunch of balloons soaring through the air

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Limited (ASX: MSB) share price rocketed on news that the company's drug, rexlemestrocel-L, is showing promising signs.

The Mesoblast share price closed today's trade 14.29% higher at $2.56 per share. Notably, today is the highest its shares have been since the failure of remestemcel-L in treating COVID-19 patients was announced in late December.

Why is the Mesoblast share price soaring?

Mesoblast announced that a single dose of its drug rexlemestrocel-L provides a reduction in heart attacks, strokes and cardiac death in patients with chronic heart failure.

The results come from its landmark, randomised controlled phase 3 trial with 537 patients. Of the patients, who all had chronic heart failure, some received rexlemestrocel-L and others received a control sham. The study found that a single dose of the drug resulted in a substantial and durable reduction in heart attacks, strokes, and cardiac deaths. The patients were monitored for 30 months after the dose was administered.

Since the existing therapies have very minimal benefit on these same endpoints, Mesoblast claims that these results may signal a breakthrough in addressing certain unmet needs with patients who have chronic heart failure.

Heart attacks and strokes were reduced by 60% from a single dose, while incidence of death from rexlemestrocel-L was also reduced by the same amount. Across the board the drug reduced all 3 outcomes of death by 30%.

This comes as a sharp turnaround from the news Mesoblast released on 15 December that there was no reduction in the recurrent non-fatal decompensated heart failure events from the drug, which caused its share price to fall by 15%.

Chronic heart failure affects 6.5 million people in the US and 26 million globally, with those numbers increasing in prevalence and incidence every year.

About the Mesoblast share price

The Mesoblast share price was particularly volatile in 2020, rising as high as $5.70 and dropping as low as $1.02. Nonetheless the recent news has pushed shares in the company higher, resulting in a 1-year return of 11.79%.

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A diverse group of people form a circle at a park and raise their arms together.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors pulled back from the market's record highs this Thursday.

Read more »

A few gold nullets sit on an old-fashioned gold scale, representing ASX gold shares.
Broker Notes

This ASX 200 gold stock could shine bright, says top broker

Poised to soar?

Read more »

Three miners looking at a tablet.
Resources Shares

3 ASX mining shares to sell today: experts

These iron ore, coal, and lithium miners have attracted sell ratings from brokers.

Read more »

Five different piggy banks, indicating a diverse share portfolio.
Bank Shares

Investing in ASX 200 banks: Which macroeconomic variables matter according to Macquarie

The majority of absolute bank performance can be explained by four key factors.

Read more »

Happy miner giving ok sign in front of a mine.
Broker Notes

Macquarie forecasts 40% upside for this ASX mining stock

Ready to rock.

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why DroneShield, EOS, Larvotto, and Life360 shares are racing higher today

These shares are having a strong session. But why?

Read more »

A man holds his head in his hands after seeing bad news on his laptop screen.
Share Fallers

Why Beach Energy, Cettire, Flight Centre, and Pilbara Minerals shares are sinking today

These shares are having a tough time on Thursday. But why?

Read more »

Red arrow going downwards in front of oil pumpjacks.
Energy Shares

Why did this $2.7 billion ASX 200 energy share just crash 11%?

Investors are fleeing the ASX 200 energy stock today. But why?

Read more »